Patrick Conway, MD, MSc, joined Blue Cross and Blue Shield of North Carolina as president and CEO-elect on Oct. 1, 2017. He will succeed Brad Wilson as CEO at Wilson’s retirement by the end of 2017. Conway most recently served as Deputy Administrator for Innovation and Quality at the federal Centers for Medicare and Medicaid Services (CMS). In this role he also held the position of Director of the Center for Medicare and Medicaid Innovation (CMMI). As the most senior non-political leader at CMS, he worked in both Republican and Democratic administrations and is considered one of the driving forces behind the national movement to value-based care, with health care payments tied to quality and innovation. At Blue Cross NC, Conway is continuing that commitment to delivering the best health outcomes and best service experience at the lowest cost for customers. Read his full bio.

Interview with Patrick Conway of Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation. It was an honor to lead the dynamic Center during a major health care shift in our country. I had the pleasure to direct and work alongside very talented leaders and staff to develop, test, spread and scale payment models and stand up key delivery system reform policies. CMMI was one avenue in creating a platform to test new approaches to health care payment and delivery while improving the value of care for Americans. We initiated major changes to make real progress in transforming the health care system during my tenure. We made it a priority to actively seek stakeholder feedback and utilized human-centered design approaches.

There are myriad accomplishments from my CMS career in which I take great pride, specifically from my CMMI tenure. Through dedicated efforts, we received CMMI’s first actuarial certifications to expand the Medicare Diabetes Prevention Program (DPP) and Pioneer Accountable Care Organization (ACO) model. The Medicare DPP model aimed to prevent type 2 diabetes for individuals with pre-diabetic indicators. We closely collaborated with the National Institutes of Health, Centers for Disease Control and YMCA to encourage lifestyle changes in people with high risk for the disease. This evidence- and community-based prevention program demonstrated that costs could be lowered and quality could be raised – and those improvements could be sustained. The Pioneer ACO model was very successful, allowing providers to transition from a shared savings payment model to a population-based model, separate and apart from the Medicare Shared Savings Program.

In addition, we partnered with the states of Maryland and Vermont to modernize the all-payer model for hospital services to improve patient healthcare and reduce costs. We also developed the Oncology Care model (OCM) to begin tackling the effectiveness and efficiency of specialty care for Americans. Specifically, OCM worked with physician practices and commercial payers to enhance care coordination and chemotherapy treatment for cancer patients. We also developed the Comprehensive Care for Joint Replacement model to begin addressing episodic care associated with hip and knee replacements in this country – the most common inpatient surgeries – to improve quality and coordination of care through recovery.

Lastly, we developed the Quality Payment Program, an alternative payment model to provide incentives to clinicians participating in high-quality, valuable care for episodic care or populations. In 2012, we had 0 percent of payments in alternative payment models, where providers were accountable for quality and total cost of care. By 2016, over 30 percent of provider payments were in alternative payment models like ACOs, bundled payments, or comprehensive primary care.

The shift toward these new payment models represented over $200 billion, which is a giant leap forward for value-based health care. CMS is now headed toward 500 ACOs in the public market, and even more in the private market. Under our Delivery System Reform efforts, we collaborated with a range of stakeholders to move from volume payment of care to value payment of care. We launched the Health Care Payment Learning and Action Network to improve care, lower costs and promote healthy populations.

Q: Do you think that some kind of Medicare-for-all health insurance system could work in US health care?

A: The cost of health care is a fundamental problem facing the health industry. Collectively, we must address the prices we pay for quality health care.

Instead of creating a new health care system, we should focus on solutions that lower costs for all populations, including patients with multiple chronic conditions. It’s imperative that we collectively address rising prescription drug prices and actively work to lower these costs.

One area where we must make progress is in looking holistically at health, to include examining social determinants of health and sustaining healthy populations through focused efforts on primary and preventive care.

Americans have more personal choice in health care and insurance than anywhere else in the world. That range of options is fundamental to a health care system that offers affordable care with better health outcomes.

America’s health care system is a global leader in innovation and offers some of the world’s best hospitals and treatments. We shouldn’t give up on what’s good about our health care to build a new, unproven system.
I’ve had the pleasure of leading the country’s largest health payer and now leading North Carolina’s largest health insurer. Value-based care is crucial to a sustainable health care system that provides life-long quality care for Americans. And we all need to pick up the pace of change to bring about a value-based system.

Q: How might the Blue Cross and Blue Shield Association (BCBSA) be able to help facilitate health care system change among Blue Plans and beyond?

A: Health care is delivered locally, personally. It’s not a one-size-fits-all proposition. Health insurance has to be just as focused on the individual.

The great advantage of the collective power of Blue Plans is our deeply embedded roots in the communities we serve. Nobody knows our markets like we do, nobody has the history and relationships we have with our provider networks. Simply put, we’re best positioned to lead the transformation toward value-based, consumer-focused health care.

BCBSA plays a critical role in facilitating communication and information sharing among Blue Plans, identifying what’s working and how those successes can be scaled and replicated across the country.

BCBSA is a central source for insurance claims information, taking the lead on utilizing big data to stay out in front of emerging trends. By collecting and analyzing claims information from Blue Plans across the country, BCBSA can identify trends and even help mitigate health crises before they reach a critical stage.

BCBSA sifts through its mountains of data for monthly Health of America analysis reports. These reports help payers, providers and consumers understand why health care costs have been rising so dramatically and by making the data public, we can provide insights on consumers’ role in moving toward value-based health care.

Q: What is your perspective on the proposed mergers involving CVS and Aetna? Walmart and Humana? What are your thoughts on the business alliance of Amazon, Berkshire Hathaway, and JP Morgan? What impact, if any, would those have on US health care?

A: Mergers and alliances can create disruptive change and lead to innovation into the market. With change, there is opportunity. I don’t view these alliances or mergers as threats. They are a wake-up call for all of health care: Change must happen and it has to happen now.

With CVS-Aetna, time will tell. It will interesting to see how the companies integrate and maximize value throughout the partnership.

In terms of the Amazon-Berkshire Hathaway-JP Morgan Chase plans, my biggest takeaway is that they’re so upset with the current system that they want to disrupt it – and my reaction is, we should listen. They’re identifying a real problem; we want to be part of the solution, too.

At Blue Cross NC, we’re actively working to be the change for our customers. We are creating a value-based health care system committed to more choices, better access, lower cost and higher quality of care. We are keenly focused on primary care, social determinants of health, provider and beneficiary relationships, using human-centered design approaches to keep the focus on consumers.

Interview with Andrew Carroll of Google AI

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I believe that applying AI technologies in healthcare will make physicians more valuable, and will make their careers more enjoyable and sustainable.

Read More

Interview with L. Staton Noel III of Panaceutics

Q: What need is Panaceutics addressing?

A: One of the key barriers to making precision/personalized wellness and healthcare products is the contradictory goal of manufacturing individualized products on a large scale. Meeting demand for personalized products can be expensive and logistically challenging.

Read More

Interview with Joe Zhang of Burning Rock Dx

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: The milestones in my mind include the first FDA clearance of Next Gen Sequencing instrument, MiSeqDx in 2013, this opened a new door for clinical utilization of parallel gene alteration detection in clinical setting.

Read More

Why are Scientists So Upset About The First CRISPR Babies?

The use of new technologies can provide breakthrough benefits for both patients and providers. However, with increased sharing comes increased risks to the security and privacy of patient data. Currently data is being accumulated across many organizations and initiatives but is often either siloed or simply not accessible. Researchers suggest that patient education tactics can help quell security concerns during patient data sharing.

Read More

Interview with Kara Davis of Stanford

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: These immune checkpoint inhibitors have been an incredible demonstration of the ability of the immune system to control and in some cases.

Read More

Interview with Shannon J. McCall of Duke University

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: After several years of the promise of precision medicine and abundant clinical trial work, the recent FDA approval of solid-tumor-agnostic therapies dependent on molecular biomarkers has catapulted genomic/precision medicine into the standard-of-care for late stage cancer.

Read More

Interview with Tao Chen of Paragon Genomics, Inc.

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: For whole genome sequencing to be a reliable clinical tool, it will largely depend on the cost of sequencing the genome and our ability to interpret the data.

Read More

Call for Action: The Time is Now for Patient Data Interoperability

The use of new technologies can provide breakthrough benefits for both patients and providers. However, with increased sharing comes increased risks to the security and privacy of patient data. Currently data is being accumulated across many organizations and initiatives but is often either siloed or simply not accessible. Researchers suggest that patient education tactics can help quell security concerns during patient data sharing.

Read More

Interview with Andrew Magis of Arivale

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling. How soon, do you think, will we see what kind of accelerated growth?

A: I think the acceleration has already begun. Large sequencing projects such as NHLBI Trans-omics for Precision Medicine (TOPMed) and NIH All of Us are sequencing 150,000 and 1 million individuals, respectively.

Read More

Interview with Emily Leproust of Twist Bioscience

Q: NGS is enhancing patient care through improved diagnostic sensitivity and more precise therapeutic targeting. Prominent examples include cystic fibrosis and cancer. What other clinical areas NGS will most likely to change the standard-of-care in the near future?

A: Preventative medicine – using genetic data to identify traits that have the potential to cause harm in the future.

Read More

Interview with Michael Phelps of UCLA

Q: You invented the PET scanner that changed the lives of millions of patients with cancer, brain and heart diseases. What are the potential benefits to patients of combining PET with radio-ablation technologies?

A: PET provides imaging assays of the biology of disease in many diseases today.

Read More

Interview with Daniela Ushizima of Lawrence Berkeley National Lab

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I really hope that human physicians will not be replaced by machines in the foreseeable future.

Read More

Interview with Amy Compton-Phillips of Providence St. Joseph Health

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend? What technological advancements are driving this change?

A: Genomic medicine is poised to move quickly from the research realm into integration with healthcare delivery, but there is always a time lapse between technology advances and what we do with those advances.

Read More

Interview with James Taylor of Precision NanoSystems

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Patients are already receiving treatment using novel gene and cell therapies.

Read More

Interview with Julie Eggington of Center for Genomic Interpretation

Q: Together with Robert Burton you founded the Center for Genomic Interpretation (CGI), a non-profit organization. Can you tell us more about CGI and the mission behind it?

A: CGI’s mission is to drive quality in clinical genetics and genomics. CGI works primarily with laboratories, health insurance payers, clinicians, and patients/consumers.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!